৳ 15,000/unit
Pack: ৳ 15,000
৳ 15,000/unit
Pack: ৳ 15,000
At a glance
Pegfilgrastim is a leukocyte growth factor used to prevent infections after chemotherapy. It stimulates bone marrow to produce white blood cells that protect the body against infections.
Indications
- Decrease incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy associated with febrile neutropenia
Pharmacology
Pegfilgrastim is a Granulocyte Colony-Stimulating Factor (G-CSF) that regulates the production and release of functional neutrophils from bone marrow. It binds to specific cell surface receptors of hematopoietic cells, stimulating proliferation, differentiation, commitment, and end cell functional activation.
Dosage
Adult Dose (Subcutaneous):
- Chemotherapy-induced neutropenia: 6 mg single dose per chemotherapy cycle, given at least 24 hours after cytotoxic chemotherapy
- Maximum safe dose not determined (up to 300 mcg/kg evaluated)
Pediatric Dose (Subcutaneous):
- >45 kg: 6 mg per chemotherapy cycle
- Do not administer in the period 14 days before and 24 hours after cytotoxic chemotherapy
Side effects
Side Effects:
- Splenic rupture (can be fatal)
- Acute Respiratory Distress Syndrome (ARDS)
- Serious allergic reactions (anaphylaxis)
- Severe sickle cell crises in sickle cell disorders
- Bone pain
- Joint pain
- Headache
- Nausea
- Low blood platelets
- Muscle pain
- Back pain
- Injection site pain
Use in pregnancy
Use in Pregnancy: May be unsafe during pregnancy; animal studies have shown harmful effects. Doctor will weigh benefits and risks before prescribing. Pregnancy Category C.
Pregnancy Category: C — always consult a doctor before taking during pregnancy.
Precautions & warnings
- Fatal splenic rupture can occur; evaluate for splenomegaly or rupture in patients with left upper abdominal or shoulder pain
- ARDS can occur; evaluate for ARDS in patients who develop fever, lung infiltrates, or respiratory distress; discontinue Pegfilgrastim in patients with ARDS
- Serious allergic reactions including anaphylaxis can occur; permanently discontinue for serious allergic reactions
- Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders
- Do not administer with cytotoxic chemotherapy (increased risk of myelosuppression)
- Avoid driving if dizziness occurs
Overdose effects
Overdose: Maximum safe dose not determined. Single SC doses of 300 mcg/kg have been administered without serious adverse effects. Maximum ANC observed was 96x10⁹/L. Treatment: symptomatic supportive care.
Storage conditions
Store in a refrigerator at 2-8°C; do not freeze; do not shake; keep away from light.